Table 5 Changes in HRQoL and blood biomarkers measures in experimental and control groups and qualitative inferences about the intervention effects

Fact-B

5.9 (10.8)

2.1 (7.9)

3.7 (.0 to 7.5)

.18 (.00 to .35)

Possibly beneficial (59)

Fact-G

16.2 (85.1)

2.7 (8.8)

13.1 (−4.9 to 34.6)

.34 (−.14 to .82)

Possibly beneficial (69)

TOI

4.8 (31.1)

1.6 (10.2)

3.1 (−4.8 to 11.8)

.13 (−.21 to .47)

Possibly beneficial (36)

BCS

8.8 (18.5)

1.0 (28.1)

7.7 (−1.2 to 17.5)

.22 (−.04 to .47)

Possibly beneficial (54)

PWB

9.2 (16.2)

7.6 (14.6)

1.5 (−4.2 to 7.5)

.07 (−.19 to .33)

Unlikely beneficial (20)

SWB

−2.5 (12.3)

.7 (13.3)

−3.2 (−7.8 to 1.6)

−.15 (−.37 to .07)

Possibly decreases (36)

EWB

5.6 (13.5)

5.6 (9.7)

−.0 (−4.3 to 4.5)

.00 (−0.19 to .19)

Very unlikely beneficial (5)

FWB

6.2 (20.4)

−1.3 (15.0)

7.6 (.6 to 15.2)

.26 (.02 to .50)

Possibly beneficial (66)

TC

−3.5 (10.5)

3.2 (6.7)

−6.5 (−9.6 to −3.3)

−.41 (−.62 to −.21)

Very likely beneficial (95)

HDL-C

−.7 (11.0)

1.0 (6.7)

−1.7 (−5.0 to 1.9)

−.14 (−.42 to .15)

Possibly beneficial (35)

LDL-C

−4.5 (14.9)

2.5 (12.8)

−6.8 (−11.6 to −1.8)

−.31 (−.55 to −.08)

Likely beneficial (79)

TC/LDL-C ratio

−2.3 (14.5)

1.6 (11.3)

−3.8 (−8.5 to 1.0)

−.19 (−.43 to .05)

Possibly beneficial (47)

Trig

−3.5 (16.3)

1.8 (16.4)

−5.2 (−10.9 to .8)

−.20 (−.42 to .03)

Possibly beneficial (49)

Glucose

−2.9 (6.7)

−6.1 (40.6)

3.4 (−6.7 to 14.5)

.14 (−.30 to .59)

Possibly beneficial (42)

Insulin

−3.6 (87.3)

−24.2 (145.4)

27.2 (−7.1 to 74.3)

.31 (−.09 to .70)

Possibly increases (67)

HOMA

−4.5 (39.5)

0.7 (61.6)

−5.2 (−26.6 to 22.5)

−.12 (−.72 to .47)

Possibly beneficial (41)